subject: Preclinical Models: Innovative Solutions To Accelerate Drug Discovery And Development [print this page] Preclinical Models: Innovative solutions to accelerate drug discovery and development
Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools to minimize development costs and reduce failures prior to commencement of human trials. Problems with traditional animal models such as cost, ethics, and suitability has prompted researchers to develop new models and systems to overcome such disadvantages. Alternative approaches include new vertebrate, nonvertebrate, computer-based and imaging models that offer new perspectives and utility to aid the drug discovery and development process.
This report explores novel preclinical models that show promise to expedite and improve the target validation and lead optimization timeline and discusses the various advantages and disadvantages of ADMET screening technologies to provide insight on which models or systems may enhance the R&D function of pharmaceutical and biotechnology organisations.
Additionally, the report provides an outlook for preclinical testing over the next decade and how pharmaceutical companies may need to adjust to new systems and models to improve their efficiencies. It uniquely focuses on more than 60 companies that are involved in using or developing ADMET technologies to advance preclinical research and provides an update on recent company activities and developments where new models and systems are employed to accelerate the discovery and development process.
Key features of this report
Analysis of current developments in preclinical ADMET research for drug discovery and development
Evaluation of the drivers behind innovation in preclinical research.
Identifies the current trends in ADMET research and how technology companies are developing new models to improve and accelerate discovery and development.
Analysis of current in-vivo, in-vitro, in-silico, and systems biology models that are advancing toxicity prediction in early drug discovery.
Scope of this report
Understand the basis to ADMET testing and why it is a necessary and important component of preclinical research
Up-to-date information on the preclinical models and systems currently used in drug discovery and development.
Evaluation of the key recent developments and activities of companies who are developing and licensing new ADMET technologies.
Identifies existing models and how new ones are being developed to improve productivity and knowledge.
Key Market Issues
Established preclinical models correlate poorly with human in-vivo biological responses therefore innovation is needed to approximate more accurately the human response.
Technology and software providers are developing novel models to expand the ADMET market in order to accelerate drug discovery and development.
In-vivo, in-vitro, and in-silico models are increasingly becoming more sophisticated and a push for integration is creating demand for highly efficient centralized platforms to expedite predictive ADMET insight.
Key findings from this report
Innovation in preclinical research is rapidly changing the landscape for ADMET testing and new models are accelerating decision-making in discovery and development.
Novel in-vivo, in-vitro, in-silico and systems biology models are accelerating the discovery and development timeline for pharmaceutical companies.
Demand to reduce in-vivo whole-organism ADMET testing has stimulated in-silico research but novel animal models and in-vitro screens will be needed to complement and correlate in-silico prediction.
New vertebrate and invertebrate whole organism preclinical models include humanized rodents and zebrafish that provide disease-state environments, which better predict biological responses to investigational compounds.
Key questions answered
1. What are preclinical models and how are they important to the pharmaceutical industry?
2. What are the advantages and disadvantages of preclinical models in ADMET screening?
3. What are the innovations in preclinical models?
4. What are the trends in preclinical research?
5. How are in-vivo, in-vitro, in-silico and systems biology models being developed for ADMET?
6. How are companies building ADMET capabilities?
To know more about this report & to buy a copy please visit :
